Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Commercial Officer Aziz Mottiwala departing July 15, 2026 for CEO role at a public medical device company.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercial Officer Aziz Mottiwala departing July 15, 2026 for CEO role at a public medical device company
- Commercial leadership transition creates execution risk for Tarsus’s sales and market-expansion initiatives
- Departure described as pursuing a new opportunity, with no indication of misconduct or disagreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.